The 2015 world health organization classification of tumors of the thymus continuity and changes

Journal of Thoracic Oncology

Volumn 10, Issue 10, 2015, Pages 1383-1395

  Marx, Alexander ^a   Chan, John K C ^b   Coindre, Jean Michel ^c   Detterbeck, Frank ^d   Girard, Nicolas ^e   Harris, Nancy L ^f   Jaffe, Elaine S ^g   Kurrer, Michael O ^h   Marom, Edith M ⁱ   Moreira, Andre L ^j   Mukai, Kiyoshi ^k   Orazi, Attilio ^l   Ströbel, Philipp ^m  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c INSTITUT BERGONIÉ   (France)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LOUIS PRADEL HOSPITAL   (France)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h Gemeinschaftspraxis Pathologie Zürich   (Switzerland)

ⁱ SHEBA MEDICAL CENTER   (Israel)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k SAISEIKAI CENTRAL HOSPITAL   (Japan)

^l WEILL CORNELL MEDICAL CENTER   (United States)

^m UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

more..

Author keywords

Adenocarcinoma; Atypical type A thymoma; Carcinoid; Classification; Combined large cell neuroendocrine carcinoma; Combined thymic carcinoma; Computed tomography; Cytology; Dendritic cell tumor; Ectopic tumor; Genetic; Germ cell tumor; Grey zone lymphoma; GTF2I; Histology; Hodgkin lymphoma; Immunohistochemistry; Immunohistology; International Thymic Malignancy Interest Group; Lymphoma; Mediastinal; Mediastinum; Metastasis; Neuroblastoma; Neuroendocrine; NUT carcinoma; Pathology; Positron emission tomography; Primary mediastinal large B cell lymphoma; Sarcoma; Staging; Thymic carcinoma; Thymoma; Thymus; World Health Organization

Indexed keywords

CD20 ANTIGEN; CD5 ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 20; PROTEIN P40; PROTEIN P63; STEM CELL FACTOR RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOSQUAMOUS CARCINOMA; ANGIOSARCOMA; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CHORIOCARCINOMA; CLASSICAL HODGKIN LYMPHOMA; CLEAR CELL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DENDRITIC CELL SARCOMA; EMBRYONAL CARCINOMA; GANGLIONEUROMA; GRANULOCYTIC SARCOMA; HEMANGIOMA; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LIPOMA; LIPOSARCOMA; LYMPHANGIOMA; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; MARGINAL ZONE LYMPHOMA; MEDIASTINUM CANCER; MEDIASTINUM TUMOR; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; SARCOMATOID CARCINOMA; SEMINOMA; SYNOVIAL SARCOMA; TERATOMA; THYMOMA; THYMUS ADENOCARCINOMA; THYMUS BASALOID CARCINOMA; THYMUS CANCER; THYMUS CARCINOID; THYMUS SQUAMOUS CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA; WORLD HEALTH ORGANIZATION; YOLK SAC TUMOR; CANCER GRADING; CANCER STAGING; CLASSIFICATION; PATHOLOGY;

HUMANS; NEOPLASM GRADING; NEOPLASM STAGING; THYMOMA; THYMUS NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84942513697     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000654     Document Type: Review

References (91)

1. Travis WD, Brambilla E, Müller-Hermelink HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
2. Rosai J, Sobin L. Histological Typing of Tumours of the Thymus, 1999.
3. Travis WD, Brambilla E, Burke A P, et al. WHO Classifcation of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2015.
4. Ströbel P, Hartmann E, Rosenwald A, et al. Corticomedullary differentiation and maturational arrest in thymomas. Histopathology 2014;64:557-566.
5. Marx A, Ströbel P, Badve SS, et al. ITMIG consensus statement on the use of the WHO histological classifcation of thymoma and thymic carcinoma: refned defnitions, histological criteria, and reporting. J Thorac Oncol 2014;9:596-611.
6. Weis CA, Yao X, Deng Y, et al.; Contributors to the ITMIG Retrospective Database. The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol 2015;10:367-372.
7. Ahmad U, Yao X, Detterbeck F, et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg 2015;149:95-100, 101.e101-102.
8. Huang J, Ahmad U, Antonicelli A, et al.; International Thymic Malignancy Interest Group International Database Committee and Contributors. Development of the International Thymic Malignancy Interest Group international database: an unprecedented resource for the study of a rare group of tumors. J Thorac Oncol 2014;9:1573-1578.
9. Filosso PL, Ya o X, Ahmad U, et al.; European Society of Thoracic Surgeons Thymic Group Steering Committee. Outcome of primary neu-roendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. J Thorac Cardiovasc Surg 2015;149:103-109.e2.
10. Swerdlow SH, Campo E, Harris NL, et al. WHO Classifcation of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008.
11. Fletcher CDM, Bridge JA, Hogendorn PCW, et al. WHO Classifcation of Tumours of Soft Tissue and Bone. IARC Press, 2014.
12. Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classifcation for thymic malignancies: classifcation and defnition of terms. J Thorac Oncol 2011;6(7 Suppl 3):S1710-1716.
13. th) edition of the TNM classifcation of malignant tumors. J Thorac Oncol 2014;9(9 Suppl 2):S81-S87.
14. th) edition of the TNM classifcation of malignant tumors. J Thorac Oncol 2014;9(9 Suppl 2):S73-S80.
15. th) edition of the TNM classifcation of malignant tumors. J Thorac Oncol 2014;9(9 Suppl 2):S65-S72.
16. Roden AC, Yi ES, Jenkins SM, et al. Modifed Masaoka stage and size are independent prognostic predictors in thymoma and modifed Masaoka stage is superior to histopathologic classifcations. J Thorac Oncol 2015;10:691-700.
17. Suster S, Moran CA. Histologic classifcation of thymoma: the World Health Organization and beyond. Hematol Oncol Clin North Am 2008;22:381-392.
18. Detterbeck FC. Clinical value of the WHO classifcation system of thy-moma. Ann Thorac Surg 2006;81:2328-2334.
19. Moran CA, Weissferdt A, Kalhor N, et al. Thymomas I: a clinicopath-ologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol 2012;137:444-450.
20. Ströbel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004;22:1501-1509.
21. Wang Y, Thomas A, Lau C, et al. Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep 2014;4:7336.
22. Petrini I, Meltzer PS, Kim IK, et al. A specifc missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 2014;46:844-849.
23. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-6799.
24. Petrini I, Wang Y, Zucali PA, et al. Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clin Cancer Res 2013;19:1960-1971.
25. Chen C, Yin B, Wei Q, et al. Aberrant DNA methylation in thymic epithelial tumors. Cancer Invest 2009;27:582-591.
26. Huang B, Belharazem D, Li L, et al. Anti-apoptotic signature in thymic squamous cell carcinomas-functional relevance of anti-apoptotic BIRC3 expression in the thymic carcinoma cell line 1889c. Front Oncol 2013;3:316.
27. Rajan A, Girard N, Marx A. State of the art of genetic alterations in thy-mic epithelial tumors. J Thorac Oncol 2014;9(9 Suppl 2):S131-S136.
28. Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multi-arm, multihistology phase II basket trial. J Clin Oncol 2015;33:1000-1007.
29. Marx A, Weis CA. Sunitinib in thymic carcinoma: enigmas still unresolved. Lancet Oncol 2015;16:124-125.
30. Green AC, Marx A, Strobel P, et al. Type A and AB thymomas: his-tological features associated with increased stage. Histopathology 2015;66:884-891.
31. Nonaka D, Henley JD, Chiriboga L, et al. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms. Am J Surg Pathol 2007;31:1038-1044.
32. Vladislav IT, Gokmen-Polar Y, Kesler KA, Loehrer PJ, Sr, Badve S. The role of histology in predicting recurrence of type A thymomas: a clinico-pathologic correlation of 23 cases. Mod Pathol 2013;26:1059-1064.
33. Brambilla C, Laffaire J, Lantuejoul S, et al. Lung squamous cell carcinomas with basaloid histology represent a specifc molecular entity. Clin Cancer Res 2014;20:5777-5786.
34. Brown JG, Familiari U, Papotti M, et al. Thymic basaloid carcinoma: a clinicopathologic study of 12 cases, with a general discussion of basaloid carcinoma and its relationship with adenoid cystic carcinoma. Am J Surg Pathol 2009;33:1113-1124.
35. Zhou R, Zettl A, Ströbel P, et al. Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol 2001;159:1853-1860.
36. Tonon G, Modi S, Wu L, et al. t(11;19)(q21;p13) translocation in muco-epidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 2003;33:208-213.
37. Achcar Rde O, Nikiforova MN, Dacic S, et al. Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Human pathology 2009;40:854-860.
38. Roden AC, Erickson-Johnson MR, Yi ES, et al. Analysis of MAML2 rearrangement in mucoepidermoid carcinoma of the thymus. Hum Pathol 2013;44:2799-2805.
39. Di Tommaso L, Kuhn E, Kurrer M, et al. Thymic tumor with adenoid cystic carcinoma like features: a clinicopathologic study of 4 cases. Am J Surg Pathol 2007;31:1161-1167.
40. Moser B, Schiefer AI, Janik S, et al. Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma. Am J Surg Pathol 2015;39:541-548.
41. French CA, Rahman S, Walsh EM, et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov 2014;4:928-941.
42. Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012;18:5773-5779.
43. den Bakker MA, Roden AC, Marx A, Marino M. Histologic classifcation of thymoma: a practical guide for routine cases. J Thorac Oncol 2014;9(9 Suppl 2):S125-S130.
44. Girard N. Thymic epithelial tumours: from basic principles to individualised treatment strategies. Eur Respir Rev 2013;22:75-87.
45. Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015;16:177-186.
46. Thomas A, Rajan A, Szabo E, et al. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res 2014;20:5392-5402.
47. Rajan A, Carter CA, Berman A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol 2014;15:191-200.
48. Loehrer PJ, Sr., Wang W, Johnson DH, Aisner SC, Ettinger DS; Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with predni-sone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004;22:293-299.
49. French C. NUT midline carcinoma. Nat Rev Cancer 2014;14:149-150.
50. Ströbel P, Zettl A, Shilo K, et al. Tumor genetics and survival of thymic neuroendocrine neoplasms: a multi-institutional clinicopathologic study. Genes Chromosomes Cancer 2014;53:738-749.
51. Pelosi G, Bimbatti M, Fabbri A, et al. Thymic neuroendocrine neoplasms (T-NENs) with CTNNB1 (beta-catenin) gene mutation show components of well-differentiated tumor and poorly-differentiated carcinoma, challenging the concept of secondary high-grade neuroendocrine carcinoma. Mod Pathol 2015;28 (Suppl 2):487A(#1956).
52. Moran CA, Suster S. Thymic neuroendocrine carcinomas with combined features ranging from well-differentiated (carcinoid) to small cell carcinoma. A clinicopathologic and immunohistochemical study of 11 cases. Am J Clin Pathol 2000;113:345-350.
53. Weissferdt A, Tang X, Wistuba, II, Moran CA. Comparative immunohis-tochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1. Mod Pathol 2013;26:1554-1560.
54. de Jong J, Stoop H, Gillis AJ, et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J Pathol 2008;215:21-30.
55. Looijenga LH, Stoop H, de Leeuw H P, et al. POU5F1 (OCT3/4) identifes cells with pluripotent potential in human germ cell tumors. Cancer Res 2003;63:2244-2250.
56. Zynger DL, Everton MJ, Dimov ND, Chou PM, Yang XJ. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol 2008;130:224-230.
57. Zamo A, Malpeli G, Scarpa A, Doglioni C, Chilosi M, Menestrina F. Expression of TP73L is a helpful diagnostic marker of primary mediasti-nal large B-cell lymphomas. Mod Pathol 2005;18:1448-1453.
58. Dotto J, Pelosi G, Rosai J. Expression of p63 in thymomas and normal thymus. Am J Clin Pathol 2007;127:415-420.
59. Chilosi M, Zamò A, Brighenti A, et al. Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 2003;443:175-183.
60. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifes a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-862.
61. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014;123:2062-2065.
62. Steidl C, Shah S P, Woolcock B W, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471:377-381.
63. Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary medias-tinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 2014;38:1715-1723.
64. Kominato S, Nakayama T, Sato F, et al. Characterization of chromosomal aberrations in thymic MALT lymphoma. Pathol Int 2012;62:93-98.
65. Go H, Cho HJ, Paik JH, et al. Thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a clini-copathological and genetic analysis of six cases. Leuk Lymphoma 2011;52:2276-2283.
66. Zhou Y, Fan X, Routbort M, et al. Absence of terminal deoxynucleo-tidyl transferase expression identifes a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. Mod Pathol 2013;26:1338-1345.
67. Bonn BR, Rohde M, Zimmermann M, et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 2013;121:3153-3160.
68. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10:147-156.
69. Callens C, Baleydier F, Lengline E, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 2012;30:1966-1973.
70. Burkhardt B, Bruch J, Zimmermann M, et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 2006;20:1422-1429.
71. Küppers R. New insights in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2012;2012:328-334.
72. Greaves P, Clear A, Owen A, et al. Defning characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 2013;122:2856-2863.
73. Steidl C, Diepstra A, Lee T, et al. Gene expression profling of microdis-sected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 2012;120:3530-3540.
74. Steidl C, Lee T, Shah S P, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-885.
75. Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 2011;96:558-566.
76. Eberle FC, Salaverria I, Steidl C, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol 2011;24:1586-1597.
77. Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C. Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profling. J Pathol 2006;210:155-162.
78. Behringer K, Goergen H, Hitz F, et al.; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015;385:1418-1427.
79. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408-1416.
80. LeMieux MH, Solanki AA, Mahmood U, Chmura SJ, Koshy M. Risk of second malignancies in patients with early-stage classical Hodgkin's lym-phoma treated in a modern era. Cancer Med 2015 4:513-518.
81. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic effcacy of vemu-rafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013;121:1495-1500.
82. Adam P, Hakroush S, Hofmann I, Reidenbach S, Marx A, Ströbel P. Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall. Virchows Archiv 2014;465:313-320.
83. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identifcation of recurrent NAB2-STAT6 gene fusions in solitary fbrous tumor by integra-tive sequencing. Nat Genet 2013;45:180-185.
84. Käcker C, Marx A, Mössinger K, et al. High frequency of MYC gene amplif-cation is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01. Genes Chromosomes Cancer 2013;52:93-98.
85. Manner J, Radlwimmer B, Hohenberger P, et al. MYC high level gene amplifcation is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 2010;176:34-39.
86. Ueda Y, Omasa M, Taki T, et al. Thymic neuroblastoma within a thymic cyst in an adult. Case Rep Oncol 2012;5:459-463.
87. Pellegrino M, Gianotti L, Cassibba S, Brizio R, Terzi A, Borretta G. Neuroblastoma in the elderly and SIADH: case report and review of the literature. Case Rep Med 2012;2012:952645.
88. Rennspiess D, Pujari S, Keijzers M, et al. Detection of human polyomavi-rus 7 in human thymic epithelial tumors. J Thorac Oncol 2015;10:360-366.
89. Ehemann V, Kern MA, Breinig M, et al. Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. Int J Cancer 2008;122:2719-2725.
90. Gökmen-Polar Y, Sanders KL, Goswami C P, et al. Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Lab Invest 2012;92:1564-1573.
91. Marx A, Porubsky S, Belharazem D, et al. Thymoma related myas-thenia gravis in humans and potential animal models. Exp Neurol 2015;270:55-65.